Europe OKs 1st One-Dose Drug to Protect Babies Against RSV

November 4, 2022

(Associated Press) – The European Commission has authorized the world’s first one-dose drug against a respiratory virus that sickens millions of babies and children globally every year. In a statement Friday, drugmakers Sanofi and AstraZeneca said the European Commission had given the green light to nirsevimab, a laboratory-developed antibody designed to protect infants during their first exposure to RSV, or respiratory syncytial virus, a highly contagious common infection that infects nearly all babies by age 2. (Read More)